Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
Background Lutathera is a 177Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibody, may act synergistically with lutathera to gene...
Main Authors: | Giuseppe Esposito, Giuseppe Giaccone, Chul Kim, Stephen V Liu, Deepa S Subramaniam, Tisdrey Torres, Massimo Loda |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-07-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/2/e000980.full |
Similar Items
-
Cellular dosimetry of [177Lu]Lu-DOTA-[Tyr3]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
by: Giulia Tamborino, et al.
Published: (2020-02-01) -
177Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours : Dosimetry-Based Therapy Planning and Outcome
by: Garske-Román, Ulrike
Published: (2012) -
Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate
by: Lore Santoro, et al.
Published: (2018-11-01) -
In Vivo Measurement and Characterization of a Novel Formulation of [177Lu]-DOTA-Octreotate
by: Dale Bailey, et al.
Published: (2016-01-01) -
Terapia com [177Lu – Dota0 – Tyr3]–Octreotate (177Lu-Dotatate) em Pacientes com Tumores Avançados de Origem Neuroendócrino: Experiência Inicial e Resultados Preliminares
by: Víctor Marín Oyaga, et al.
Published: (2017-10-01)